Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 3, 2014, Pages 453-461

  Barylski, Marcin ^a   Toth, Peter P ^b,c   Nikolic, Dragana ^d   Banach, Maciej ^a   Rizzo, Manfredi ^d,e   Montalto, Giuseppe ^d  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF PALERMO   (Italy)

^e Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

apoA I mimetic; coronary artery disease; delipidation; endothelial lipase inhibitor; farnesoid X receptor; high density lipoproteins; liver X receptor; reverse cholesterol transport; RVX 208

Indexed keywords

APOLIPOPROTEIN A1; ESTERASE INHIBITOR; FARNESOID X RECEPTOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR BLOCKING AGENT; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; RESERVELOGIX 208; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ARTERY INJURY; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; GENE THERAPY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; NONHUMAN; OXIDATION; THROMBOSIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DYSLIPIDEMIAS; EXPERIMENTAL THERAPY; GENETICS; PHYSIOLOGY; PROCEDURES; TRENDS; UPREGULATION;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; GENETIC THERAPY; HUMANS; THERAPIES, INVESTIGATIONAL; UP-REGULATION;

EID: 84901298334     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2013.11.001     Document Type: Review

References (63)

1. P.P. Toth Reverse cholesterol transport: high-density lipoprotein's magnificent mile Curr Atheroscler Rep 5 2003 386 393
2. W.P. Castelli, J.T. Doyle, and T. Gordon et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study Circulation 55 1977 767 772
3. N.E. Miller, D.S. Thelle, and O.H. Forde et al. The Tromsø heart-study. High-density lipoprotein and coronary heart disease: a prospective case-control study Lancet 1 1977 965 968
4. D.J. Gordon, J.L. Probstfield, and R.J. Garrison et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
5. S.J. Nicholls, E.M. Tuzcu, and I. Sipahi et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508
6. C.M. Ballantyne, J.S. Raichlen, and S.J. Nicholls et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden Circulation 117 2008 2458 2466
7. B. Brown, X. Zhao, and M. Cheung Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence J Clin Lipidol 1 2007 88 94
8. P.J. Barter, M. Caulfield, M. Eriksson ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
9. G.G. Schwartz, A.G. Olsson, M. Abt dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
10. http://www.ctsu.ox.ac.uk/%7Ethrive/.
11. W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
12. C.R. Sirtori, L. Calabresi, and G. Franceschini et al. Cardiovascular status of carriers of the apolipoprotein A-I Milano mutant: the limone sul garda study Circulation 103 2001 1949 1954
13. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
14. J.C. Tardif Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology? J Clin Lipidol 4 2010 399 404
15. B. Ibanez, C. Giannarelli, and G. Cimmino et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type) Atherosclerosis 220 2012 72 77
16. J.C. Tardif, J. Gregoire, P.L. L'Allier Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 18 2007 1675 1682
17. R. Chenevard, D. Hurlimann, and L. Spieker et al. Reconstituted HDL in acute coronary syndromes Cardiovasc Ther 30 2012 e51 e57
18. R. Waksman, R. Torguson, and K.M. Kent et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
19. F.M. Sacks, L.L. Rudel, and A. Conner et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J Lipid Res 50 2009 894 907
20. G. Datta, M. Chaddha, and S. Hama et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide J Lipid Res 42 2001 1096 1104
21. M. Navab, I. Shechter, and G.M. Anantharamaiah et al. Structure and function of HDL mimetics Arterioscler Thromb Vasc Biol 30 2010 164 168
22. L.T. Bloedon, R. Dunbar, and D. Duffy et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J Lipid Res 49 2008 1344 1352
23. C.E. Watson, N. Weissbach, and L. Kjems et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function J Lipid Res 52 2011 361 373
24. J. Ou, Z. Ou, and D.W. Jones et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease Circulation 107 2003 2337 2341
25. C.B. Sherman, S.J. Peterson, and W.H. Frishman Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis Cardiol Rev 18 2010 141 147
26. M.N. Palgunachari, V.K. Mishra, and S. Lund-Katz Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly Arterioscler Thromb Vasc Biol 16 1996 328 338
27. K.L. Gillotte, M. Zaiou, and S. Lund-Katz Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid J Biol Chem 274 1999 2021 2028
28. P. Natarajan, T.M. Forte, and B. Chu Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1 J Biol Chem 279 2004 24044 24052
29. C. Vedhachalam, V. Narayanaswami, and N. Neto The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins Biochemistry 46 2007 2583 2593
30. A.A. Sethi, J.A. Stonik, and F. Thomas Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides J Biol Chem 283 2008 32273 32282
31. J.K. Bielicki, H. Zhang, and Y. Cortez et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice J Lipid Res 51 2010 1496 1503
32. A.C. Edmondson, R.J. Brown, and S. Kathiresan et al. Loss-offunction variants in endothelial lipase are a cause of elevated HDL cholesterol in humans J Clin Invest 119 2009 1042 1050
33. K.O. Badellino, M.L. Wolfe, and M.P. Reilly et al. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis PLoS Med 3 2006 e22
34. N.P. Tang, L.S. Wang, and L. Yang et al. Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population J Lipid Res 49 2008 369 375
35. M. Vergeer, S.J.A. Korporaal, and R. Franssen et al. Genetic variant of the scavenger receptor BI in humans N Engl J Med 364 2011 136 145
36. T. Ishida, S. Choi, and R.K. Kundu et al. Endothelial lipase is a major determinant of HDL level J Clin Invest 111 2003 347 355
37. E.M. deGoma, and D.J. Rader Novel HDL-directed pharmacotherapeutic strategies Nature Rev Cardiol 8 2011 266 277
38. T.M. Teslovich, K. Musunuru, and A.V. Smith et al. Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
39. http://circ.ahajournals.org/cgi/content/meeting
40. X. Rousset, R. Shamburek, and B. Vaisman et al. Lecithin cholesterol acyltransferase: an anti- or proatherogenic factor? Curr Atheroscler Rep 13 2011 249 256
41. S. Asada, M. Kuroda, and Y. Aoyagi et al. Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy Am J Phys 301 2011 C181 C185
42. D.J. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 2006 3090 3100
43. D. Bailey, R. Jahagirdar, and A. Gordon et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 2010 2580 2589
44. A. Gordon, R. Jahagirdar, and J. Johannson et al. RVX-208 a small molecule that induces apolipoprotein A-I production progresses to phase Ib/IIa clinical trials Proceedings of the American College of Cardiology Scientific Sessions, Orlando, Fla, USA 2009
45. S.J. Nicholls, A. Gordon, and J. Johansson et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease: a randomized controlled trial J Am Coll Cardiol 57 2011 1111 1119
46. S.J. Nicholls, A. Gordon, and J. Johannson et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies Cardiovasc Drugs Ther 26 2012 181 187
47. P.K. Shah Atherosclerosis: targeting endogenous apoA-I - a new approach for raising HDL Nature Rev Cardiol 8 2011 187 188
48. G. Lo Sasso, S. Murzilli, and L. Salvatore et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis Cell Metab 12 2010 187 193
49. M.H. Oosterveer, A. Grefhorst, and A.K. Groen et al. The liver X receptor: control of cellular lipid homeostasis and beyond: implications for drug design Prog Lipid Res 49 2010 343 352
50. T. Yasuda, D. Grillot, and J.T. Billheimer et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo Arterioscler Thromb Vasc Biol 30 2010 781 786
51. E. Rigamonti, L. Helin, and S. Lestavel et al. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages Circ Res 97 2005 682 689
52. E.M. Quinet, M.D. Basso, and A.R. Halpern et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse J Lipid Res 50 2009 2358 2370
53. A. Katz, C. Udata, and E. Ott et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of lxr-623, a novel liver X-receptor agonist, in healthy participants J Clin Pharmacol 49 2009 643 649
54. M.N. Bradley, C. Hong, and M. Chen et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE J Clin Invest 117 2007 2337 2346
55. D. Peng, R.A. Hiipakka, and J.T. Xie et al. Anovel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR-/- mice Br J Pharmacol 162 2011 1792 1804
56. A. Mencarelli, and S. Fiorucci FXR an emerging therapeutic target for the treatment of atherosclerosis J Cell Mol Med 14 2010 79 92
57. E. Hambruch, S. Miyazaki-Anzai, and U. Hahn et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice J Pharmacol Exp Ther 343 2012 556 567
58. S. Fiorucci, S. Cipriani, and F. Baldelli et al. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders Prog Lipid Res 49 2010 171 185
59. A.S. Plump, C.J. Scott, and J.L. Breslow Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Natl Acad Sci U S A 91 1994 9607 9611
60. N. Maeda, H. Li, and D. Lee et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia J Biol Chem 269 1994 23610 23616
61. K.J. Rayner, F.J. Sheedy, and C.C. Esauet et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis J Clin Invest 121 2011 2921 2931
62. T.J. Marquart, R.M. Allen, and D.S. Ory et al. miR-33 links SREBP-2 induction to repression of sterol transporters Proc Natl Acad Sci U S A 107 2010 12228 12232
63. T. Horie, K. Ono, and M. Horiguchi et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo Proc Natl Acad Sci U S A 107 2010 17321 17326